| Literature DB >> 30498268 |
E Staderini1, R Patini1, M De Luca1, P Gallenzi1.
Abstract
The aim of this systematic review is to analyse the quality and clinical evidence in the literature analysing, through 3D stereophotogrammetry, the nasolabial soft tissue modifications that may occur after rapid maxillary expansion (RME). This systematic literature review was based on the PRISMA-P statement and was registered in the PROSPERO database with the following protocol ID: CRD42017079875. Pubmed, Cochrane, EBSCO, Scopus, Web of Science databases were searched with no restriction of year or publication status. Selection criteria were: randomised clinical trials, controlled clinical trials, cohort studies, cross-sectional studies, case-control studies on patients with unilateral/bilateral crossbite, transverse maxillary deficiency and crowding, treated with RME and monitored by 3D stereophotogrammetry. 652 articles were retrieved in the initial search. After the review process, 11 full-text articles met inclusion criteria. After the evaluation process, 4 publications were included for the present literature review. Due to the heterogeneous methodology meta-analysis was not possible; consequently, a systematic assessment of the studies and summary of the findings from the available evidence were used to answer the research question. The maximum widening of the alar cartilage is 1.41 ± 0.95 mm, whose clinical significance is open to question. The effect of RME on the mouth width remains controversial. In Altindis et al., the difference between pre-treatment and post-treatment mouth width (1.80 mm increment in the banded RME group) was statistically significant, while in Baysal 1.86 mm was considered a non-significant value. Inconsistencies and limitations in the study population and measurement protocols were detected between studies. These data underline the necessity for updated guidelines that allow to standardise, for this type of study, sample selection, measurement methods and collection of results.Entities:
Keywords: Dentofacial orthopaedics; Face; Growth; Nose; Photogrammetry; Soft tissue; Systematic review
Mesh:
Year: 2018 PMID: 30498268 PMCID: PMC6265666 DOI: 10.14639/0392-100X-2059
Source DB: PubMed Journal: Acta Otorhinolaryngol Ital ISSN: 0392-100X Impact factor: 2.124
Study selection criteria.
| Randomised clinical trials (RCTs), controlled clinical trials (CCTs), cohort studies, cross-sectional studies, case-control studies | |
| Studies on patients with unilateral or bilateral cross-bite, maxillary transverse deficiency, crowding | |
| Homogeneous patients not receiving RME treatment | |
Full electronic search strategy.
| Database | Search strategy |
|---|---|
| Pubmed (free text words) | ((((((((orthodontics*[All Fields]) OR jaw*[All Fields]) OR face*[All Fields]) OR (growth and development*[All Fields])) OR malocclusion*[All Fields]))) AND (((((((female*[All Fields]) OR male*[All Fields]) OR child*[All Fields]) OR adult*[All Fields]) OR adolescent*[All Fields]) OR epidemiologic studies*[All Fields]))) AND (((((diagnosis*[All Fields]) OR determination*[All Fields]) OR assessment*[All Fields]) OR evaluation*[All Fields]) OR treatment outcomes*[All Fields]))) AND (photogrammetry*[All Fields]) |
| Pubmed MeSh | ((((((((orthodontics*[MeSh]) OR jaw*[MeSh]) OR face*[MeSh]) OR (growth and development*[MeSh])) OR malocclusion*[MeSh]))) AND (((((((female*[MeSh]) OR male*[MeSh]) OR child*[MeSh]) OR adult*[MeSh]) OR adolescent*[MeSh]) OR epidemiologic studies*[MeSh]))) AND (((((diagnosis*[MeSh]) OR determination*[MeSh]) OR assessment*[MeSh]) OR evaluation*[MeSh]) OR treatment outcomes*[MeSh]))) AND (photogrammetry*[MeSh]) |
| Scopus | ((TITLE-ABS-KEY (orthodontics*)) OR (TITLE-ABS-KEY (jaw*)) OR (TITLE-ABS-KEY (face*)) OR (TITLE-ABS-KEY (growth AND development*)) OR (TITLE-ABS-KEY (malocclusion*))) AND ((TITLE-ABS-KEY (female*)) OR (TITLE-ABS-KEY (male*)) OR (TITLE-ABS-KEY (child*)) OR (TITLE-ABS-KEY (adolescent*)) OR (TITLE-ABS-KEY (epidemiologic AND studies*))) AND ((TITLE-ABS-KEY (diagnosis*)) OR (TITLE-ABS-KEY (assessment*)) OR (TITLE-ABS-KEY (evaluation*)) OR (TITLE-ABS-KEY (determination*)) OR (TITLE-ABS-KEY (treatment AND outcomes* ))) AND (TITLE-ABS-KEY (photogrammetry*)) |
| Cochrane Central (Free Text Words) | (orthodontics* OR jaw* OR face* OR growth and development* OR malocclusion*) AND (male* OR female* OR child* OR adult* OR adolescent* OR epidemiologic studies*) AND (diagnosis* OR assessment* OR evaluation OR determination* OR treatment outcomes*) AND photogrammetry* |
| Cochrane Central MeSh | ((MeSH orthodontics) OR (MeSH jaw) OR (MeSH face) OR (MeSH Growth AND Development) OR (MeSH Malocclusion)) AND ((MeSH diagnosis) OR (MeSH Outcomes AND Process Assessment) OR (MeSH Evaluation Studies as Topic) OR (MeSH Treatment outcome)) AND ((MeSH male) OR (MeSH female) OR (MeSH child) OR (MeSH adult) OR (MeSH Adolescent) OR (MeSH Epidemiologic Studies)) AND (MeSH Photogrammetry) |
| Web of Science | (TS=(orthodontics*) OR TS=(jaw*) OR TS=(face*) OR TS=(growth and development*) OR TS=(malocclusion*)) AND (TS=(male*) OR TS=(female*) OR TS=(child*) OR TS=(adult*) OR TS=(adolescent*) OR TS=(epidemiologic studies*)) AND (TS=(diagnosis*) OR TS=(assessment*) OR TS=(evaluation) OR TS=(determination*) OR TS=(treatment outcomes*)) AND (TS=(photogrammetry*)) |
| EBSCO MeSh | (MH orthodontics* OR MH jaw* OR MH face* OR MH jaw diseases* OR MH (growth and embryonic development*) OR MH malocclusion*) AND (MH Photogrammetry*) AND (MH male* OR MH female* OR MH child* OR MH adult* OR MH child development: 5 years* OR MH child development: 6-11 years* OR MH child development: 11-17 years* OR MH experimental studies*) AND (MH diagnosis* OR MH outcome assessment* OR MH evaluation* OR MH treatment outcomes*) |
Fig. 1.PRISMA flow diagram for the identification and selection of studies.
Table showing references of excluded studies with rationale for exclusion.
| References | Rationale for exclusion |
|---|---|
| Bishara et al., 1995 | 3D analysis not performed |
| Cummins et al., 1995 | 3D analysis not performed |
| Kamonji, 1980 | 3D analysis not performed |
| Kim et al., 2016 | Patients not treated with RME |
| Matzler et al., 2014 | Patients not treated with RME |
| Rune et al., 1980 | 3D analysis on hard tissue and not on soft tissue |
| Singh, 2002 | Patients not treated with RME |
Patient characteristics and quality of evidence of the included studies.
| Trial | Setting | Sample size | Mean age (years) | Mean time between image acquisitions | Type of appliance | Skeletal development | Quality of the evidence (SBU grading system)[ |
|---|---|---|---|---|---|---|---|
| Altındiş et al., 2016 [ | RCT | 42 (18 M, 24 F) | Banded RME:[ | NA | [ | NA | B |
| Altorkat et al., 2016 [ | Case-series | 14 (7 M, 7 F) | 12.6 ± 1.8 | NA | Bonded RME | NA | C |
| Baysal et al., 2016 [ | RCT | 34 (18 M, 16 F) | Exp: | 6.1 months | Bonded RME | NA | B |
| Dindaroğlu et al., 2016 [ | RCT | 50 (26 M, 24 F) | Exp: | 15.6 days | Bonded RME | Not exceeding MP3 cap stage | B |
1 Articles were graded according to the SBU criteria as follow: 1) grade A (High level of evidence): randomised controlled trials (RCTs) or prospective study with a well-defined control group; presence of defined diagnosis and endpoints; well-described diagnostic reliability tests and reproducibility tests; blinding outcome assessment. 2) grade B (Moderate level of evidence): same criteria as grade A except for the blinding outcome assessment. 3) grade C (Low level of evidence): articles that do not meet the criteria of grade A and B.
SBU tool permitted to assess the level of the available evidence of the systematic review accordingly to the following classification: 1) strong: at least two studies of level A; 2) moderate: one study of level A and at least two studies of level B; 3) limited: at least two studies of level B; 4) scarce: fewer than two studies of level B.
**Please note: in Altındiş et al. [
Definitions of soft tissue landmarks and comparison of mean differences between the included studies.
| Comparisons of treatment changes among the groups (mm) | ||||
|---|---|---|---|---|
| Abbreviation | Definition | Altındiş et al. [ | Altorkat et al. [ | Baysal et al. [ |
| AlR-AlL | Distance between left and right alar: point located at left and right labial commissure | 1.35 ± 1.08 | 1.6 (1.00 – 2.02) | 1.42 ± 0.96 |
| ChR-ChL | Distance between left and right chelion: most lateral point on left and right alar contour | 1.80 ± 1.85 | - | 1.86 ± 1.35 |
* Please note: the study of Dindaroğlu et al. [23] does not report linear distances (AlR-AlL and ChR-ChL), but volumetric 3-D deviations. Therefore, Dindaroğlu’s data are not included in this table.
Risk of bias assessment.
| Study | Rating scale | ||
|---|---|---|---|
| Baysal 2016 [ | Cochrane’s collaboration tool for assessing the risk of bias | ||
| Items | Low risk | High risk | Unclear risk of bias |
| Randomisation | x | ||
| Allocation | x | ||
| Blinding participant and personnel | x | ||
| Blinding outcome assessor | x | ||
| Missing outcome data | x | ||
| Selective reporting | x | ||
| Other bias | x | ||
| Randomisation | x | ||
| Allocation | x | ||
| Blinding participant and personnel | x | ||
| Blinding outcome assessor | x | ||
| Missing outcome data | x | ||
| Selective reporting | x | ||
| Other bias | x | ||
| Randomisation | x | ||
| Allocation | x | ||
| Blinding participant and personnel | x | ||
| Blinding outcome assessor | x | ||
| Missing outcome data | x | ||
| Selective reporting | x | ||
| Other bias | 3-month follow-up | x | x |
| Representativeness | x | ||
| Selection | x | ||
| Sample size | x | ||
| Non-respondent | x | ||
| Exposure | x | ||
| Comparability | x | ||
| Outcome assessment | x | ||
| Statistical test | x | ||